The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Akt-dependent and -independent mechanisms of mTOR regulation in cancer
Open accessAbstract
The protein kinase mTOR (mammalian target of rapamycin) is a critical regulator of cellular metabolism, growth, and proliferation. These processes contribute to tumor formation, and many cancers are characterized by aberrant activation of mTOR. Although activating mutations in mTOR itself have not been identified, deregulation of upstream components that regulate mTOR are prevalent in cancer. The prototypic mechanism of mTOR regulation in cells is through activation of the PI3K/Akt pathway, but mTOR receives input from multiple signaling pathways. This review will discuss Akt-dependent and independent mechanisms of mTOR regulation in response to mitogenic signals, as well as its regulation in response to energy and nutrient-sensing pathways. Preclinical and clinical studies have demonstrated that tumors bearing genetic alterations that activate mTOR are sensitive to pharmacologic inhibition of mTOR. Elucidation of novel pathways that regulate mTOR may help identify predictive factors for sensitivity to mTOR inhibitors and could provide new therapeutic targets for inhibiting the mTOR pathway in cancer. This review will also highlight pharmacologic approaches that inhibit mTOR via activation of the AMP-activated protein kinase (AMPK), an important inhibitor of the mTOR pathway and an emerging target in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · cited 1×
“Amino acid stimulation also increases the GTP-loading and activity of the Rag-GTPases in cells [68].”
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., & Hardie, D. G. (2003) · Journal of Biology · doi:10.1186/1475-4924-2-28 · Cited by 1,665
A serine/threonine kinase gene defective in Peutz–Jeghers syndrome
Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A., Bignell, G., Warren, W., Aminoff, M., Höglund, P., et al. (1998) · Nature · doi:10.1038/34432 · Cited by 1,656
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.009 · Cited by 1,589
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Akt Stimulates Aerobic Glycolysis in Cancer Cells
Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., Zhuang, H., Cinalli, R. M., Alavi, A., Rudin, C. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2904 · Cited by 1,454
Woods, A., Dickerson, K., Heath, R., Hong, S.-P., Momcilovic, M., Johnstone, S. R., Carlson, M., & Carling, D. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.06.005 · Cited by 1,392
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 2×
“REDD1 acts upstream of the TSC1/2 complex because hypoxia does not inhibit mTORC1 in cells deficient for TSC1 or TSC2, even when REDD1 is overexpressed [56].”
DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis
Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P. R., Gasco, M., Garrone, O., Crook, T., & Ryan, K. M. (2006) · Cell · doi:10.1016/j.cell.2006.05.034 · Cited by 1,380 · cited 1×
“Under conditions of nutrient deprivation, stabilization of p53 induces autophagy [95].”
Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.055 · Cited by 1,377
Gene expression profiling identifies clinically relevant subtypes of prostate cancer
Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., Ferrari, M., Egevad, L., Rayford, W., Bergerheim, U., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304146101 · Cited by 1,292
Phosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268 · cited 1×
“Studies performed using mass spectrometry and Scansite, an internet-based bioinformatics platform that analyzes protein phosphorylation motifs, identified S664 and S540 as putative ERK phosphorylation sites in TSC2 [30].”
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · cited 1×
“Akt-mediated phosphorylation of PRAS40 attenuates its inhibitory effect on mTORC1 [24,25].”
Corton, J. M., Gillespie, J. G., Hawley, S. A., & Hardie, D. G. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.0558k.x · Cited by 1,230
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
Delcommenne, M., Tan, C., Gray, V., Rue, L., Woodgett, J., & Dedhar, S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11211 · Cited by 1,092
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
LKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling
Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., & Chen, J. (2001) · Science · doi:10.1126/science.1066015 · Cited by 1,055
Role of Translocation in the Activation and Function of Protein Kinase B
Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31515 · Cited by 1,051
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2
Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., & Thomas, G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00220-x · Cited by 1,043
The Ca2+/Calmodulin-dependent Protein Kinase Kinases Are AMP-activated Protein Kinase Kinases
Hurley, R. L., Anderson, K. A., Franzone, J. M., Kemp, B. E., Means, A. R., & Witters, L. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503824200 · Cited by 1,018
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
NAVÉ, B. T., Ouwens, D. M., Withers, D. J., Alessi, D. R., & Shepherd, P. R. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3440427 · Cited by 932
Cool, B., Zinker, B., Chiou, W., Kifle, L., Cao, N., Perham, M., Dickinson, R., Adler, A., Gagne, G., Iyengar, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.005 · Cited by 925
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923
Management of cellular energy by the AMP‐activated protein kinase system
Hardie, D. G., Scott, J. W., Pan, D. A., & Hudson, E. R. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00560-x · Cited by 855
Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823
Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806
Nobukuni, T., Joaquin, M., Roccio, M., Dann, S. G., Kim, S. Y., Gulati, P., Byfield, M. P., Backer, J. M., Natt, F., Bos, J. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506925102 · Cited by 757
DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D., & Ellisen, L. W. (2008) · Genes & Development · doi:10.1101/gad.1617608 · Cited by 710 · cited 3×
“Interestingly, studies that analyzed REDD1 expression in primary breast or invasive prostate carcinomas demonstrated that REDD1 expression was decreased in ~30% of these samples compared to patient-matched normal epithelium [59,63].”
Sekulić, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., & Abraham, R. T. (2000) · PubMed · Cited by 710
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade
Sanders, M. J., Grondin, P. O., Hegarty, B. D., Snowden, M. A., & Carling, D. (2007) · Biochemical Journal · doi:10.1042/bj20061520 · Cited by 666
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
Sánchez‐Céspedes, M., Parrella, P., Esteller, M., Nomoto, S., Trink, B., Engles, J. M., Westra, W. H., Herman, J. G., & Sidransky, D. (2002) · PubMed · Cited by 612
Corradetti, M. N., Inoki, K., Bardeesy, N., DePinho, R. A., & Guan, K.-L. (2004) · Genes & Development · doi:10.1101/gad.1199104 · Cited by 560
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C. L., & Kwiatkowski, D. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17222 · Cited by 538
hVps34 Is a Nutrient-regulated Lipid Kinase Required for Activation of p70 S6 Kinase
Byfield, M. P., Murray, J. T., & Backer, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507201200 · Cited by 527
Akt/Protein Kinase B Is Regulated by Autophosphorylation at the Hypothetical PDK-2 Site
Toker, A., & Newton, A. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8271 · Cited by 516
Meikle, L., Pollizzi, K., Egnor, A., Kramvis, I., Lane, H., Sahin, M., & Kwiatkowski, D. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0955-08.2008 · Cited by 501
Holmes, B. F., Kurth-Kraczek, E. J., & Winder, W. W. (1999) · Journal of Applied Physiology · doi:10.1152/jappl.1999.87.5.1990 · Cited by 489
Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase
Feng, J., Park, J., Cron, P., Hess, D., & Hemmings, B. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406731200 · Cited by 488
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
Arsham, A. M., Howell, J. J., & Simon, M. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212770200 · Cited by 463 · cited 1×
“Hypoxia (1% O2) rapidly inhibits basal levels of mTORC1 activity in cells, and prevents insulin and growth factor-induced mTORC1 activation [55].”
Maschek, G., Savaraj, N., Priebe, W., Braunschweiger, P., Hamilton, K., Tidmarsh, G. F., De Young, L. R., & Lampidis, T. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3294 · Cited by 451
Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1
Sofer, A., Lei, K., Johannessen, C. M., & Ellisen, L. W. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.5834-5845.2005 · Cited by 449
Frech, M., Andjelkovic, M., Ingley, E., Reddy, K. K., Falck, J. R., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.13.8474 · Cited by 446
Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein Kinase
Göransson, O., McBride, A., Hawley, S. A., Ross, F. A., Shpiro, N., Foretz, M., Viollet, B., Hardie, D. G., & Sakamoto, K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706536200 · Cited by 435
Balendran, A., Casamayor, A., Deak, M., Paterson, A., Gaffney, P., Currie, R., Downes, C. P., & Alessi, D. R. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80186-9 · Cited by 429
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Huang, X., Wullschleger, S., Shpiro, N., McGuire, V. A., Sakamoto, K., Woods, Y. L., Mcburnie, W., Fleming, S., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20080557 · Cited by 396
Kimura, N., Tokunaga, C., Dalal, S., Richardson, C., Yoshino, K., Hara, K., Kemp, B. E., Witters, L. A., Mimura, O., & Yonezawa, K. (2003) · Genes to Cells · doi:10.1046/j.1365-2443.2003.00615.x · Cited by 372
Exton, J. H. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00089-x · Cited by 366
Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner
Kovacina, K. S., Park, G. Y., Bae, S. S., Guzzetta, A. W., Schaefer, E., Birnbaum, M. J., & Roth, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210837200 · Cited by 364
Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning
Cai, S.-L., Tee, A. R., Short, J. D., Bergeron, J. M., Kim, J., Shen, J., Guo, R., Johnson, C. L., Kiguchi, K., & Walker, C. L. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200507119 · Cited by 359
Buzzai, M., Bauer, D. E., Jones, R. G., DeBerardinis, R. J., Hatzivassiliou, G., Elstrom, R. L., & Thompson, C. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208622 · Cited by 357
Smith, E. M., Finn, S. G., Tee, A. R., Browne, G. J., & Proud, C. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414499200 · Cited by 355
Rattan, R., Giri, S., Singh, A. K., & Singh, I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507443200 · Cited by 339
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., Le, L., Oza, A., Nicklee, T., Ho, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603419 · Cited by 317
Hornberger, T. A., Chu, W. K., Mak, Y. W., Hsiung, J. W., Huang, S. A., & Chien, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600678103 · Cited by 312
A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy
Lee, M.-J., Feliers, D., Mariappan, M. M., Sataranatarajan, K., Mahimainathan, L., Musi, N., Foretz, M., Viollet, B., Weinberg, J. M., Choudhury, G. G., et al. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00278.2006 · Cited by 285
Yee, K. W. L., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0764 · Cited by 285
Mohanti, B. K., Rath, G. K., Anantha, N., Kannan, V., Das, B. S., Chandramouli, B. A. R., Banerjee, A. K., Das, S., Jena, A., Ravichandran, R., et al. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)85017-6 · Cited by 281
WALKER, K. S., DEAK, M., PATERSON, A., HUDSON, K., COHEN, P., & ALESSI, D. R. (1998) · Biochemical Journal · doi:10.1042/bj3310299 · Cited by 278
Xie, Z., Dong, Y., Scholz, R., Neumann, D., & Zou, M.-H. (2008) · Circulation · doi:10.1161/circulationaha.107.744490 · Cited by 273
Chan, J. A., Zhang, H., Roberts, P. S., Jozwiak, S., Wieslawa, G., Lewin-Kowalik, J., Kotulska, K., & Kwiatkowski, D. J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.12.1236 · Cited by 258
A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling
Findlay, G. M., Yan, L., Procter, J., Mieulet, V., & Lamb, R. F. (2007) · Biochemical Journal · doi:10.1042/bj20061881 · Cited by 257
Novel G Proteins, Rag C and Rag D, Interact with GTP-binding Proteins, Rag A and Rag B
Sekiguchi, T., Hirose, E., Nakashima, N., Ii, M., & Nishimoto, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004389200 · Cited by 254
Recurrent Lymphangiomyomatosis after Transplantation: Genetic Analyses Reveal a Metastatic Mechanism
Karbowniczek, M., Astrinidis, A., Balsara, B. R., Testa, J. R., Lium, J. H., Colby, T. V., McCormack, F. X., & Henske, E. P. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-969oc · Cited by 254
Components of a Calmodulin-dependent Protein Kinase Cascade
Anderson, K. A., Means, R. L., Huang, Q.-H., Kemp, B. E., Goldstein, E. G., Selbert, M. A., Edelman, A. M., Fremeau, R. T., & Means, A. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.48.31880 · Cited by 253
Corradetti, M. N., Inoki, K., & Guan, K.-L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c400557200 · Cited by 237
Lynch, D. K., Ellis, C. A., Edwards, P. A., & Hiles, I. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203258 · Cited by 214
Stahmann, N., Woods, A., Carling, D., & Heller, R. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00383-06 · Cited by 209
Phospholipase D confers rapamycin resistance in human breast cancer cells
Chen, Y., Zheng, Y., & Foster, D. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206565 · Cited by 196
El-Hashemite, N., Zhang, H., Henske, E. P., & Kwiatkowski, D. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13044-9 · Cited by 196
Phospholipase D1 is an effector of Rheb in the mTOR pathway
Sun, Y., Fang, Y., Yoon, M.-S., Zhang, C., Roccio, M., Zwartkruis, F. J., Armstrong, M., Brown, H. A., & Chen, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712268105 · Cited by 179
PLD1 Regulates mTOR Signaling and Mediates Cdc42 Activation of S6K1
Fang, Y., Park, I.-H., Wu, A.-L., Du, G., Huang, P., Frohman, M. A., Walker, S. J., Brown, H. A., & Chen, J. (2003) · Current Biology · doi:10.1016/j.cub.2003.11.021 · Cited by 177
Xie, Z., Dong, Y., Zhang, M., Cui, M.-Z., Cohen, R. A., Riek, U., Neumann, D., Schlattner, U., & Zou, M.-H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511178200 · Cited by 172
Hill, M. M., Feng, J., & Hemmings, B. A. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00973-9 · Cited by 172
Li, Y., Inoki, K., Vacratsis, P., & Guan, K.-L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300862200 · Cited by 163
Zhu, Z., Jiang, W., McGinley, J. N., & Thompson, H. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0453 · Cited by 157
Carretero, J., Medina, P. P., Blanco, R., Smit, L., Tang, M., Roncador, G., Maestre, L., Conde, E., López‐Ríos, F., Clevers, H. C., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209951 · Cited by 156
Lin, X. J., Zhang, F., Bradbury, C. M., Kaushal, A., Li, L., Spitz, D. R., Aft, R., & Gius, D. R. (2003) · PubMed · Cited by 149
Castillo, S. S., Brognard, J., Petukhov, P. A., Zhang, C., Tsurutani, J., Granville, C. A., Li, M., Jung, M., West, K. A., Gills, J. G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1530 · Cited by 124
Self-citationAICA‐Riboside: Safety, Tolerance, and Pharmacokinetics of a Novel Adenosine‐Regulating Agent
Dixon, R., Gourzis, J. T., McDermott, D., Fujitaki, J. M., Dewland, P. M., & Gruber, H. E. (1991) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1991.tb03715.x · Cited by 104
Beyond AICA riboside: In search of new specific AMP‐activated protein kinase activators
Guigas, B., Sakamoto, K., Taleux, N., Reyna, S. M., Musi, N., Viollet, B., & Hue, L. (2009) · IUBMB Life · doi:10.1002/iub.135 · Cited by 86
Han, S., Santos, T. M., Puga, A. C., Roy, J., Thiele, E. A., McCollin, M., Stemmer-Rachamimov, A. O., & Ramesh, V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3277 · Cited by 83
Voß, M., Weernink, P. A. O., Haupenthal, S., Möller, U., Cool, R. H., BAUER, B. E., Camonis, J., Jakobs, K. H., & Schmidt, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34691 · Cited by 81
Suppression of Peutz-Jeghers Polyposis by Targeting Mammalian Target of Rapamycin Signaling
Wei, C., Amos, C. I., Zhang, N., Wang, X., Rashid, A., Walker, C. L., Behringer, R. R., & Frazier, M. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4007 · Cited by 71
Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras
Shi, M., Yang, Z., Garcia, A., Xu, L., & Foster, D. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.09.003 · Cited by 69
AMP-Activated Protein Kinase Is Activated by the Stimulations of Gq-Coupled Receptors
Kishi, K., Yuasa, T., Minami, A., Yamada, M., Hagi, A., Hayashi, H., Kemp, B. E., Witters, L. A., & Ebina, Y. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3417 · Cited by 67
Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells
Varshney, R. K., Dwarakanath, B. S. R., & Jain, V. (2005) · International Journal of Radiation Biology · doi:10.1080/09553000500148590 · Cited by 65
LKB1 mutation in large cell carcinoma of the lung
Zhong, D., Guo, L., de Aguirre, I., Liu, X., Lamb, N. E., Sun, S., Gal, A. A., Vertino, P. M., & Zhou, W. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.05.018 · Cited by 60
Luna, V., Casauban, L., Sajan, M. P., Gomez-Daspet, J., Powe, J. L., Miura, A., Rivas, J., Standaert, M. L., & Farese, R. V. (2006) · Diabetologia · doi:10.1007/s00125-005-0112-4 · Cited by 55
Memmott, R. M., Gills, J. J., Hollingshead, M. G., Powers, M. C., Chen, Z., Kemp, B. E., Kozikowski, A. P., & Dennis, P. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3091 · Cited by 53
Self-citationTopical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Rauktys, A., Lee, N. Y., Lee, L., & Dabora, S. L. (2008) · BMC Dermatology · doi:10.1186/1471-5945-8-1 · Cited by 48
Watanabe, H., Yokozeki, T., Yamazaki, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402610200 · Cited by 44
Wangpaichitr, M., Savaraj, N., Maher, J. C., Kurtoğlu, M., & Lampidis, T. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2334 · Cited by 35
Targeting mTOR-mediated survival signals in anticancer therapeutic strategies
Foster, D. A. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.4.691 · Cited by 34
Govindarajan, B., Mizesko, M. C., Miller, M. S., Onda, H., Nunnelley, M., Casper, K. A., Brat, D. J., Cohen, C., Arbiser, J. L., & Nunnelly, M. (2003) · PubMed · Cited by 34
Jiang, W., Zhu, Z., & Thompson, H. J. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20425 · Cited by 33
Heminger, K., Jain, V. K., Kadakia, M., Dwarakanath, B. S. R., & Berberich, S. J. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2812 · Cited by 30
Cited by
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Targeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
Targeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
A pan-cancer proteomic perspective on The Cancer Genome Atlas
Akbani, R., Ng, P. K. S., Werner, H. M. J., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J.-Y., Yoshihara, K., Li, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms4887 · Cited by 607
The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics
Bautista-Sánchez, D., Arriaga-Canon, C., Pedroza-Torres, A., De La Rosa-Velázquez, I. A., González-Barrios, R., Contreras-Espinosa, L., Montiel-Manríquez, R., Castro-Hernández, C., Fragoso-Ontiveros, V., Álvarez-Gómez, R. M., et al. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.03.003 · Cited by 549
Metadata
- Authors
- Memmott, R. M., & Dennis, P. A.
- Venue
- Cellular Signalling
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 21
- Issue
- 5
- Pages
- 656-664
- ISSN
- 0898-6568 (ISSN-L)
- OpenAlex
- W1978608178
- Cited by
- 382
- References
- 116
- FWCI
- 12.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.